SCOTUS Oral Arguments in FTC v. Actavis; Court to Decide Legality of Pay-For-Delay (Reverse Payment) Settlement Agreements

On Monday, 25 March 2013, the Supreme Court of the United States heard oral arguments in the case, Federal Trade Commission v. Actavis, Inc., et. al. This case had previously been captioned as Federal Trade Commission v. Watson Pharmaceuticals, et. al., but was recaptioned after the combination of Actavis and Watson. KEI filed an amicus brief in support of the FTC which is available here (along with additional background to the case). Continue Reading

Uncategorized

March 27, 2013 meeting on IP Chapter of the proposed U.S.-European Union Transatlantic Trade and Investment Partnership

TACD meeting on IP Chapter for TTIP

On March 27, from noon to 3 pm, the IP Policy Committee of TACD will hold a meeting on the intellectual property chapter of the proposed U.S.-European Union Transatlantic Trade and Investment Partnership (TTIP).

The meeting will be held at KEI’s offices at 1621 Connecticut Avenue NW, Suite 500, Washington, DC 20009

Continue Reading

Uncategorized

Analysis of Kirtsaeng v. John Wiley & Sons (Parallel Importation Case); Supreme Court Applies International Exhaustion

Today, 19 March 2013, the Supreme Court released its opinion in Kirtsaeng v. John Wiley & Sons, a case involving the parallel importation of copyrighted works. The case involved the petitioner, Kirtsaeng, purchasing textbooks in Thailand then reselling them in the United States. The Second Circuit held in this case that the first sale doctrine did not apply to foreign made goods, applying national exhaustion principles. Continue Reading

Uncategorized

Notes from the March 18, 2013 NIH Call on the ritonavir March-In Request

On Monday, March 18, 2013, the National Institutes of Health (NIH), held a conference call with the four NGOs that filed an October 25, 2012 march-in request for the patents held by Abbott Laboratories/AbbVie relevant to the manufacture and sale of ritonavir, a federally funded invention that is much more expensive in the United States than in Canada, Europe or other high-income countries, and is only available as a co-formulated product with AbbVie’s version of lopinavir. Continue Reading

Uncategorized

5 March 2013-WTO TRIPS Council-Intervention of Brazil on LDC request for an extension to the transition period

On Tuesday, 5 March 2013, Brazil delivered the following statement at the WTO TRIPS Council in favor of the LDC Group’s request for an extension to the transition period. The draft decision, if adopted as outlined in proposal (IP/C/W/583), would permit an LDC member not to apply the provisions of the TRIPS Agreement, other than Articles 3, 4 and 5, until they ceased to be an LDC.

Here is Brazilian intervention in full.

Continue Reading

Uncategorized